Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

549

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis (RMS)

Interventions

BIOLOGICAL: Ublituximab
DRUG: Teriflunomide
DRUG: Oral Placebo
DRUG: IV Placebo

Sponsor

TG Therapeutics, Inc.